This could open new therapeutic avenues for the use of BDNF-loaded chitosan microspheres in models of CNS pathology, such as Parkinson’s, Alzheimer’s disease or spinal cord injury therapies. The gene discussed is BDNF; the disease is early-onset autosomal dominant Alzheimer disease.